Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Evening El, just thinking if the recent update was because of real clinical usage I would have thought an rns was warranted? So difficult to get a positive lasting rise in sp it seems, surely the tide has to turn sometime?
Evening adrianz, agree with your thoughts and I would love to know why DC left....can’t just have been over one rns. Need a new high profile CEO promptly and a clear strategy statement if this is to move forward. AR appointment imo achieved very little, ship is directionless and rudderless under his leadership....could still be a winner but needs a strong hand with clear direction, and soon.
Despite TBs heartfelt concerns the mms have marked the sp up a bit, perhaps they are more concerned about a high profile CEO announcement and TexRAD clinical integration? Interesting times ahead, hopefully the BOD are working feverishly to remove the impasse.
Morning Hors, back to sunny skies with FDBK also hopefully. Agree with your likely announcement thoughts, just a question of when. Would be nice to have a train of good news for a change to get the sp where it ought to be...imo somewhere north of 5p on current status alone. Keep smiling.
Evening Hors, yes the sp is surprisingly resilient. DC was seen as the man to deliver on the promise, sadly it hasn’t worked out.....would love to know why, can’t just be the funding rns. The next CEO needs to be more than a scientist he has to have the drive and acumen to take TexRAD to clinical sales, and quickly. Still no public announcement about the USA patent and intent to apply for FDA approval, astonishing. Guess the waiting continues.
Go on Hors, you do the honours. We really do need to know what this is all about and as El has found it in the public domain FDBK cannot claim privacy or market sensitive info as a reason not to disclose. If it is an FDA approval application then it is very significant imo.
Hi El, if this is a new application it could be very interesting but then if so why have the BOD not issued an rns? I don’t think a nomad would have barred it given the potential significance, and likely success bearing in mind TexRAD has been reviewed in several leading USA institutions already over the past few years. Just the sort of update that would spur the sp....but alas they leave it to a PI to discover, flabbergasted!
Always equates to a stagnating / falling sp. the BOD issued that poor rns for the fundraise that wasn’t imminently required and the sp has drifted down since. Is there really no news to deliver? What about an update on product development ie further CE marks, or perhaps a date for clinical sales, maybe even discussions ongoing with JVs? I know it’s the summer doldrums but we have had nothing of real interest for months. In fact the sp is still lower than 12 months ago...is there no news?
Morning El, certainly very quiet I wonder if that is due to nothing coming from FDBK for ages? Lack of information is a way of life for this company but it doesn’t help the sp. strange that mms have not marked it down though. Don’t think there is a lot of stock on their hands so why haven’t they? Do we anticipate news soon, I am not expecting an announcement since the ‘placing’ own Goal rns. Summer doldrums set in?
Hi Bo, you are so right it is the product adoption rate, clinical sales, that everything hinges upon. Get it right with the right people and the sp will soar, but we need to see figs and projections.....come on BOD you must have some idea!
OK as it’s the silly season season hat do we reckon the sp will be at end 2018?
Pros: TB gone, new BOD seems to have a clear strategy, ? Alliance / UK clinical sales later this year, could be another CE announcement, maybe a further JV announcement
Cons: possible fundraise with dilution to ?30%, expect higher losses this year due to end of research sales of TexRADand higher salaries, JVs may not happen or be deferred.
So where do you reckon we will be?
Afternoon all, another very good day and not just the brilliant weather. BOD have been engineering this for a while in my opinion and there clearly should be much more to come. Think back 12 months or so pre-CE and the sp was approaching 5p! With all that has happened since we should be well ahead of that now, so next week, barring more own goals, we should see a steady advance imo. To sustain the rise we will need to see a very positive rns, is that around the corner? But lth’s will know better than to get carried away, I stand by my cautious comments. Enjoy the weekend and anticipate a good week to come.
Afternoon Hors, agree the market needs FDBK to come out from behind the curtain and tell us some expected figures or at least clues on product development, new CE marking, clinical sales timeframe and profitability schedule. With so little information it is hardly surprising there is little support. A Trading Update addressing these points would allow a significant gain in the sp.....perhaps there is a reason they don’t want the sp to raise too far just yet, me a cynic!
Morning all, assuming a fundraise is on the cards will FDBK create shares via a Placing or a Rights Issue? If a Placing is favoured will an RNS designed to pump up the sp be delayed until after the Placing, so that favoured investors, directors and possibly institutions sit on immediate profits at the expense of us ordinary shareholders who see only dilution? On the other hand a Rights Issue would allow all who opted to take up their Rights the chance to at least benefit from a favourable RNS to offset some effect of the dilution. Two assumptions are made, that a fundraise is likely and that an RNS is due. Of course if a favourable RNS were issued prior to a fundraise in order to improve the sp then that would be far more ethical in my book. But if there is a Private Placing, followed by a favourable RNS after the new shares are listed then imo us ordinary shareholders have been screwed. Let us hope a positive Trading Update precedes a Rights Issue if a fundraise occurs.
Chores before footie El? Agree the Board do not appear to have been too clever the last week or so, strange given all that experience that they should have missed opportunities and then shot themselves in the foot. Unless of course they are planning a blockbuster for Monday, we can but hope.
Afternoon El, yes more buys than sells and you noticed the late notified 500,000 that is a buy not a sell. Looks to be set for a positive start next week, could be a good time for an RNS before the Meeting. Certainly needs to move closer to 3p than 2p if there is to be a placing. What is your take on the next week, no TR1 so assume the big holders are not accumulating.
Either way Brooko the Company have got to stop the slide ahead of any placing if one is likely in the next few months and I really do think a a trading Update is needed with as much information about revenue prospects going forward as the Nomad will allow. Horrible being an investor at the moment but fascinating to see the politics play out.